SubsidieMeestersThe World’s Only Bioprosthetic Auto-regulated Artificial Heart: From Total Artificial Heart (TAH) to Physiologic Heart Replacement Therapy (PHRT)
Carmat's Aeson® is an advanced total artificial heart designed to replace native ventricles, offering a physiological alternative to heart transplants for advanced heart failure patients.
Projectdetails
Introduction
At Carmat we have designed and developed Aeson®, the world’s most advanced total artificial heart (TAH), aiming to fulfill an unmet medical need by providing a credible therapeutic alternative to heart transplants for people suffering from end-stage biventricular heart failure.
Device Overview
Aeson® is an active implantable medical device intended to replace the ventricles of the native heart in patients suffering from advanced heart failure. The device is electro-hydraulically driven with a shape close to that of a human heart.
Functionality
Once the Aeson® is powered, it mimics the action of a normal heart, providing mechanical circulatory support and restoring normal blood flow through the body.
Unique Features
Aeson® differs from other existing artificial hearts (or TAH – total artificial hearts) in its unique combination of three features:
- Pulsatility
- Autoregulation
- Hemocompatibility
With Aeson®, Carmat is creating a new therapeutic class of “physiologic heart replacement therapy” (PHRT).
Financiële details & Tijdlijn
Financiële details
| Subsidiebedrag | € 2.500.000 |
| Totale projectbegroting | € 11.560.168 |
Tijdlijn
| Startdatum | 1-10-2022 |
| Einddatum | 30-6-2025 |
| Subsidiejaar | 2022 |
Partners & Locaties
Projectpartners
- CARMATpenvoerder
Land(en)
Vergelijkbare projecten binnen EIC Accelerator
| Project | Regeling | Bedrag | Jaar | Actie |
|---|---|---|---|---|
The first Total Artificial Heart (TAH) that truly mimics the human heart and has the potential to revolutionise the marketThe Realheart TAH system aims to provide a permanent, efficient, and adaptable artificial heart solution for end-stage heart failure patients, with trials planned for validation. | EIC Accelerator | € 2.500.000 | 2022 | Details |
A revolutionary technology platform for providing life-saving treatment for end-stage heart failure patientsreBEAT is an innovative heart support technology that safely assists both sides of the heart, aiming to improve treatment accessibility and cost-effectiveness for end-stage heart failure patients. | EIC Accelerator | € 2.499.999 | 2023 | Details |
Acorai Heart Monitor - Non-invasive multi-sensor device for heart failure monitoringThe Acorai Heart Monitor is a non-invasive device using machine learning to estimate cardiac pressure in heart failure patients, aiming to improve treatment outcomes and reduce hospitalizations. | EIC Accelerator | € 2.299.633 | 2023 | Details |
Innovative, minimally invasive device to support the natural movement of the heart in heart failure patientsSyntach CS is an innovative implantable device that restores natural heart movement in patients with left ventricular heart failure, enhancing cardiac function through synchronized support. | EIC Accelerator | € 2.500.000 | 2022 | Details |
The first heart failure therapy management point-of-care device with multiplex and multimodal sensorCardioCap is a handheld POC device that uses a finger-prick blood sample to simultaneously assess heart failure severity through four biomarkers, aiming to reduce re-hospitalization and mortality rates by 30%. | EIC Accelerator | € 2.499.999 | 2025 | Details |
The first Total Artificial Heart (TAH) that truly mimics the human heart and has the potential to revolutionise the market
The Realheart TAH system aims to provide a permanent, efficient, and adaptable artificial heart solution for end-stage heart failure patients, with trials planned for validation.
A revolutionary technology platform for providing life-saving treatment for end-stage heart failure patients
reBEAT is an innovative heart support technology that safely assists both sides of the heart, aiming to improve treatment accessibility and cost-effectiveness for end-stage heart failure patients.
Acorai Heart Monitor - Non-invasive multi-sensor device for heart failure monitoring
The Acorai Heart Monitor is a non-invasive device using machine learning to estimate cardiac pressure in heart failure patients, aiming to improve treatment outcomes and reduce hospitalizations.
Innovative, minimally invasive device to support the natural movement of the heart in heart failure patients
Syntach CS is an innovative implantable device that restores natural heart movement in patients with left ventricular heart failure, enhancing cardiac function through synchronized support.
The first heart failure therapy management point-of-care device with multiplex and multimodal sensor
CardioCap is a handheld POC device that uses a finger-prick blood sample to simultaneously assess heart failure severity through four biomarkers, aiming to reduce re-hospitalization and mortality rates by 30%.
Vergelijkbare projecten uit andere regelingen
| Project | Regeling | Bedrag | Jaar | Actie |
|---|---|---|---|---|
SPARK - Subcutaneous Pump and Advanced Remote KitHet project ontwikkelt een innovatief hartondersteuningssysteem met een subcutane sensor voor betere behandeling van gevorderd hartfalen. | Mkb-innovati... | € 199.138 | 2023 | Details |
biomimetic engineered chordae tendineae for valve repair and regenerationThis project aims to develop and validate BioChord, a bioengineered regenerative chordae tendineae for mitral valve repair, enhancing durability and promoting tissue restoration. | ERC Proof of... | € 150.000 | 2023 | Details |
Surgical optogenetic bioprinting of engineered cardiac muscleLIGHTHEART aims to revolutionize heart failure treatment by developing a surgical bioprinting tool that uses optogenetics to create engineered cardiac muscle directly at the patient's heart. | ERC Starting... | € 1.499.705 | 2023 | Details |
Transcription Factor Gene Therapy for BradyarrhythmiasPacingCure's TRACTION project aims to optimize and validate BradyTx-01, a gene therapy for cardiac pacing dysfunctions, ensuring safety, efficacy, and a pathway to commercialization. | EIC Transition | € 2.499.968 | 2023 | Details |
building vascular networks and Blood-Brain-Barriers through a Biomimetic manufacturing Technology for the fabrication of Human tissues and ORgansTHOR aims to revolutionize tissue engineering by creating patient-specific, fully functional human tissues using bioinspired mini-robots, eliminating the need for organ transplants. | EIC Pathfinder | € 3.994.150 | 2023 | Details |
SPARK - Subcutaneous Pump and Advanced Remote Kit
Het project ontwikkelt een innovatief hartondersteuningssysteem met een subcutane sensor voor betere behandeling van gevorderd hartfalen.
biomimetic engineered chordae tendineae for valve repair and regeneration
This project aims to develop and validate BioChord, a bioengineered regenerative chordae tendineae for mitral valve repair, enhancing durability and promoting tissue restoration.
Surgical optogenetic bioprinting of engineered cardiac muscle
LIGHTHEART aims to revolutionize heart failure treatment by developing a surgical bioprinting tool that uses optogenetics to create engineered cardiac muscle directly at the patient's heart.
Transcription Factor Gene Therapy for Bradyarrhythmias
PacingCure's TRACTION project aims to optimize and validate BradyTx-01, a gene therapy for cardiac pacing dysfunctions, ensuring safety, efficacy, and a pathway to commercialization.
building vascular networks and Blood-Brain-Barriers through a Biomimetic manufacturing Technology for the fabrication of Human tissues and ORgans
THOR aims to revolutionize tissue engineering by creating patient-specific, fully functional human tissues using bioinspired mini-robots, eliminating the need for organ transplants.